Can a new drug combo outperform standard care for a tough blood cancer?

NCT ID NCT07754799

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial is testing whether adding the drug venetoclax to different chemotherapy regimens can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It compares three experimental combinations against the standard treatment in 320 patients aged 14 and older. The goal is to find the most promising regimen to take forward into a larger study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax combined with chemotherapy drugs (daunorubicin, cytarabine, liposome mitoxantrone, azacitidine)
What this could lead to: If successful, this trial could identify a more effective initial treatment for acute myeloid leukemia, potentially improving remission rates and survival.
What could go wrong: This is a phase II trial, so results are preliminary. The experimental combinations may not prove better than standard care and could carry additional side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML)

More trials for these conditions

Other studies related to the condition(s) this trial covers.